Trial Outcomes & Findings for Effect of Age on Latanoprost 0.005% in Patients With Glaucoma (NCT NCT00224289)

Results Overview

Subjects applied topical latanoprost at bedtime for 8 weeks

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

17 participants

Primary outcome timeframe

At baseline (before treatment)

Results posted on

2012-12-10

Participant milestones
Measure	Topical Latanoprost All participants will be taking Latanoprost; This study compares efficacy within age groups. Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Overall Study STARTED	17
Overall Study COMPLETED	17
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

Baseline characteristics by cohort
Measure	Topical Latanoprost n=17 Participants All participants will be taking Latanoprost; This study compares efficacy within age groups. Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Age Continuous	61.6 years STANDARD_DEVIATION 12.2 • n=5 Participants
Sex: Female, Male Female	9 Participants n=5 Participants
Sex: Female, Male Male	8 Participants n=5 Participants

Timeframe: At baseline (before treatment)

Subjects applied topical latanoprost at bedtime for 8 weeks

Outcome measures
Measure	Topical Latanoprost n=17 Participants All participants will be taking Latanoprost; This study compares efficacy within age groups. Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Pre-Treatment IOP (Intraocular Pressure)	21.8 mm Hg Standard Deviation 6.28

Timeframe: 8 Weeks

Subjects applied topical latanoprost at bedtime for 8 weeks

Outcome measures
Measure	Topical Latanoprost n=17 Participants All participants will be taking Latanoprost; This study compares efficacy within age groups. Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Post-Treatment IOP (Intraocular Pressure)	18.3 mm Hg Standard Deviation 5.36

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Adverse event data not reported

Other adverse events
Measure	Topical Latanoprost n=17 participants at risk All participants will be taking Latanoprost; This study compares efficacy within age groups. Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks
Eye disorders Red Eye w/ Foreign Body Sensation	5.9% 1/17 • Adverse event information was collected for 8 weeks per subject. The subjects received the study medication for 8 weeks.
Eye disorders Eye Tearing	5.9% 1/17 • Adverse event information was collected for 8 weeks per subject. The subjects received the study medication for 8 weeks.
Eye disorders Blurry Vision	5.9% 1/17 • Adverse event information was collected for 8 weeks per subject. The subjects received the study medication for 8 weeks.

Principal Investigator

Phone: 203-785-6288